89bio
89bio.com
Health Care
Cardiometabolic Therapeutics
Biologics & Biosimilars
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
89bio, Inc. Announces Agreement to be Acquired by Roche
- 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity
Read more
Report
H.C. Wainwright Backs 89bio (ETNB) with Buy Rating
89bio, Inc. (NASDAQ:ETNB) is one of the Top 10 Stocks Under $10 That Could Triple. On September 4, H.C. Wainwright started coverage of 89bio, Inc. (NASDAQ:ETNB) with a Buy rating and a price target of $32. The firm sees strong potential in 89bio, Inc.'s (
Read more
Report
Why 89bio Stock Lagged the Market Today
89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue. The company traded sideways during the sess
Read more
Report
Report
Why Shares of 89bio Plummeted on Tuesday
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Francisco
United States
Regional office
Locations
655 Montgomery Street, Suite 1500, San Francisco, CA 94111, US